Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has reported favorable results from their Phase 1b ACCENT trial at the American Association of Cancer Research annual meeting, showcasing that their drug narmafotinib is safe and shows promising efficacy in treating advanced pancreatic cancer. The trial revealed a 100% disease control rate with the drug demonstrating excellent pharmacokinetics, supporting daily dosing. This milestone has sparked interest for further discussions with experts and potential partners in the oncology field.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
